Brepocitinib 30 mg beat placebo in dermatomyositis; 15 mg did not

Brepocitinib, an oral drug that blocks the enzymes TYK2 and JAK1, improved dermatomyositis at its higher dose but not its lower one in the phase 3 VALOR trial [s1]. The 30 mg dose beat placebo on a composite disease-activity score and on skin measures, and it did so while causing more serious infections — a benefit and a safety cost that a reader should weigh together, not separately [s1].

Dermatomyositis is a rare autoimmune disease that inflames muscle and skin, causing weakness and a distinctive rash, and it is often managed with glucocorticoids and other immunosuppressants that carry their own long-term harms. Brepocitinib is described as a first-in-class, selective TYK2-JAK1 inhibitor that dampens the cytokine signalling implicated in the disease [s1]. VALOR is the pivotal trial that tested whether that mechanism translates into measurable benefit.

What the trial did

VALOR was a phase 3, double-blind, randomised, placebo-controlled trial that assigned 241 adults with dermatomyositis in a 1:1:1 ratio to once-daily oral brepocitinib 30 mg (81 patients), 15 mg (81), or placebo (79) for 52 weeks, continuing standard therapy while tapering glucocorticoids [s1]. The primary endpoint was the Total Improvement Score, a validated composite myositis index running from 0 to 100, where higher scores mean greater improvement, measured at week 52 [s1].

The result

At week 52 the mean Total Improvement Score was 46·5 with brepocitinib 30 mg, 37·5 with 15 mg and 31·2 with placebo [s1]. The 30 mg dose was significantly better than placebo, with a difference of 15·3 (95% CI 6·7–24·0; p<0·001) [s1]. The 15 mg dose was not: its difference from placebo was 6·3, with a confidence interval spanning zero (95% CI −2·4 to 14·9) [s1]. That dose split matters — it means the effect is real at the tested top dose but that a lower, potentially safer dose could not be shown to work [s1].

The 30 mg dose was also superior to placebo across all nine key secondary endpoints, including skin disease activity, glucocorticoid tapering and physical function, with improvements seen as early as week 4 [s1]. Those secondary wins matter for interpretation: the Total Improvement Score is a validated but abstract composite, and a reader cannot feel a number on a 0-to-100 index. The glucocorticoid-tapering result is more tangible, because long-term steroids are exactly the harm patients most want to escape, and the trial enrolled people whose disease had resisted previous therapy — a group with few alternatives [s1]. The 15 mg failure is a genuine finding, not a footnote: it removes the option of the lower dose as a proven, lower-exposure choice, leaving only the dose that carried the clearer safety cost [s1].

The skin picture, in detail

A prespecified secondary analysis in JAMA Dermatology reported the skin outcomes for the same 241 participants — a population that was mostly female (187, or 77·6%) with a mean age of 50·6 years — and it is worth reading because the skin disease is often what patients feel most [s2]. On the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score, the 30 mg dose produced a mean change of −6·4 versus −3·5 for placebo (difference −3·0; 95% CI −4·6 to −1·4; p<0·001) [s2]. A clinically meaningful CDASI-A response was reached by 27 patients (33·3%) on 30 mg versus 14 (17·7%) on placebo, and itch remission by 31 (38·3%) versus 15 (19·0%) [s2]. Among the 155 patients (64·3%) with moderate-to-severe skin disease at baseline, 20 (43·5%) on 30 mg reached functional skin remission versus 11 (20·8%) on placebo [s2]. These are meaningful separations, but several confidence intervals are wide, reflecting the modest size of a trial in a rare disease [s2].

Safety

The cost sits alongside the benefit. Serious infections were more frequent in the 30 mg group than in the placebo group — 10% versus 1% [s1]. No deaths occurred during the trial [s1]. The safety profile was otherwise described as consistent with approved JAK and TYK2 inhibitors [s2], a class that already carries boxed warnings in many countries for infection and other risks. Both papers report a trial funded by Priovant Therapeutics [s1][s2]; the manufacturer's emphasis on efficacy should be read next to the tenfold difference in serious infections, not apart from it.

What it means

VALOR is a genuine positive trial — the first phase 3 win of its kind in a disease with few options — but the useful reading is conditional. Benefit was shown at 30 mg, not 15 mg, and it came with a real infection signal, so any eventual use would turn on selecting patients for whom active, refractory disease outweighs that risk. This is not a treatment decision a reader can make from a headline; it is exactly the kind of trade-off that belongs with a specialist. What the trial establishes is that blocking TYK2-JAK1 changes the course of dermatomyositis — at a price that has to be counted in the same breath.

Sources

• [s1] A Phase 3 Trial of Brepocitinib in Dermatomyositis. New England Journal of Medicine, 28 March 2026. https://doi.org/10.1056/NEJMoa2503531
• [s2] Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial. JAMA Dermatology, 26 August 2026. https://doi.org/10.1001/jamadermatol.2026.3199